Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia [Phase 2]

View source ↗

Summary

Phase 2 trial results for BMN-111 (vosoritide) in infants and young children with achondroplasia have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• BMN-111 (vosoritide)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Achondroplasia | Phase 2 | Status: COMPLETED | Results posted: 2024-06-13